Dupixent® (dupilumab) demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial

First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo

REGN Ratings Summary

REGN Quant Ranking